Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P13 SC vs IV in Crohn's Disease and Ulcerative Colitis
NCT02883452Phase 1Completed
- Sponsor
- Celltrion
- Start
- Sep 2016
- Primary completion
- Feb 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of infliximab-dyyb in Crohn's disease and ulcerative colitis (UC) (6 arms), sponsored by Celltrion. Primary endpoints: Area Under the Concentration-time Curve at Steady State at Week 28 and Observed Trough Concentration at Week 22. Started Sep 2016; status: completed.
02
Drugs
infliximab-dyyb
03
Conditions
Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02883452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02883452.